Immunization

New study results show that there are more incidences of this inflammation of the heart muscle related to not being vaccinated than there are to the vaccine itself.

Results of an analysis show that 3 doses of either Oxford/AstraZeneca COVID-19 or Pfizer BioNTech COVID-19 neutralizes the variant.

A sizable number of clinical trial participants say they had at least 1 AE, with fatigue and headaches the most common.

A new analysis suggests that boosters can provide ongoing prevention of death and hospitalization.

Amid the COVID-19 pandemic, health care providers are focusing on the health of younger individuals.

Vaccines can help protect against certain strains of HPV, the virus that causes genital warts.

Pharmacists should stay abreast of changes in formulations and recommendations, foster communication with their staff, and plan proactively.

Earlier analyses also demonstrated the same potential of BBV152 against SARS-CoV-2 alpha, beta, delta, zeta, and kappa.

These individuals also receive immunosuppressive drugs that often impair the immune responses to the vaccinations, study results show.

The research team hypothesized that younger people having more social contacts across age groups and the timing of vaccinations could have made a difference.

A single shot protects for up to 6 months against breakthrough infections, hospitalizations, and intensive care unit admissions, Johnson & Johnson says.

A goiter may be associated with an increase or decrease in thyroid hormones.

The recommendations include full immunization, including third doses and/or any approved boosters.

Results of a separate analysis demonstrate that Johnson & Johnson’s booster generated a 41-fold increase in neutralizing antibodies and a 5-fold increase in T-cells against omicron.

Study predicts the future of antibody testing may move toward technologically advanced platforms that can test for multiple antibody types in a single blood sample.

Ronald T. Piervincenzi, PhD, CEO of US Pharmacopeia, explains how pharmacists and USP came together in 2021 to work harder than ever before, as well as what can be done now to prepare for the next health crisis.

Ronald T. Piervincenzi, PhD, CEO of US Pharmacopeia, discusses the challenges that lie ahead as we move into the third year of the COVID-19 pandemic, as well as other major developments on the horizon for pharmacists in 2022.

Ronald T. Piervincenzi, PhD, CEO of US Pharmacopeia, discusses what stands out as the biggest challenge from the past year and what role USP and pharmacists had in overcoming that challenge.

Investigators in a clinical study evaluating the safety, tolerability, and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine in children aged 6 months to under 5 years noted that their research will continue with new changes.

Technology, COVID-19, and scope expansion—here’s how pharmacists can capitalize on opportunities coming in the new year.

Immunizations are very important for the winter season, and knowing how to gather safely for the holidays can make a big difference in staying healthy.

Primary and secondary endpoints for which data are available were met in a trial dominated by variants.

The emergency use authorization is based on the agency’s previous analysis of immune response data that supported use of a dose for individuals aged 18 years and older.

Results of analysis suggest that pharmacists can play a crucial role in increasing annual vaccinations.

Despite how it is sometimes portrayed in pop culture, chickenpox is far from funny and is, in fact, preventable.